Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany

Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany

  

Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 Growth to Hinge on the Success of Personalized Vaccine Following Early
Approval in Germany
Research, a leading business intelligence provider, has released its latest research report:
“Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to
Hinge on the Success of Personalized Vaccine Following Early Approval in Germany”. Due
to the poor prognosis under currently available treatments, therapies with high potency
are in strong demand in the Glioblastoma Multiforme (GBM) market. In newly diagnosed
patients, the current standard of care, comprising resection surgery, radiation therapy and
chemotherapy with Merck’s Temodar (temozolomide), has a maximum Overall Survival
(OS) of 15 months and almost inevitable tumor recurrence.

To Brows a Full Report with Toc: http://www.researchmoz.us/glioblastomamultiforme-therapeutics-in-major-developed-markets-to-2019-growth-to-hinge-on-thesuccess-of-personalized-vaccine-following-early-approval-in-germany-report.html
Current therapeutic options for recurrent GBM are Roche’s Avastin (bevacizumab),
carmustine and other chemotherapy drugs used off-label. However, they only offer limited
OS benefit, leaving high unmet need in this patient segment. During the 2012–2019
forecast period, the GBM market is expected to grow rapidly from $305m to $583m. The
market entry of Northwest Biotherapeutics’ DCVax-L, a dendritic cell-based therapeutic
vaccine that acts as an add-on to the standard treatment in newly diagnosed patients, will
account for much of this growth. Having demonstrated superior OS improvement
compared with the standard treatment alone in clinical trials, it is expected to bear high
market potential, given that its efficacy is translated into larger Phase III trials. The cancer
vaccine Rindopepimut (CDX-110) and targeted therapy Cotara will also enter the GBM
market, but will drive growth to a...

Similar Essays